GlassScriptPhysician profile
Brittany Mccall
NPI 1861997751
$3,204.45
in general payments reported to CMS, 2019-2025
43 companies · $2,712 in 2025
The $2,712 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $492 · 2025: $2,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,188 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.46 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $310.06 | 2024-2025 | Enhertu, Calquence, Lynparza |
| Janssen Biotech, INC. | $249.32 | 2024-2025 | Rybrevant, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $207.24 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.19 | 2024-2025 | Opdivo, Reblozyl |
| Pfizer INC. | $176.57 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.87 | 2025 | |
| Celgene Corporation | $130.17 | 2024-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $121.52 | 2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $116.66 | 2024-2025 | Iclusig, Fruzaqla |
| Merck Sharp & Dohme LLC | $112.26 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Geron Corporation | $101.74 | 2025 | Rytelo |
| Astellas Pharma US INC | $100.89 | 2024-2025 | Vyloy, Padcev |
| Beone Medicines USA, INC. | $99.66 | 2025 | Brukinsa, Tevimbra |
| Sobi, INC | $94.39 | 2024-2025 | |
| Adc Therapeutics America, INC. | $80.94 | 2024-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $70.68 | 2024-2025 | |
| Exelixis INC. | $61.16 | 2025 | Cabometyx |
| Karyopharm Therapeutics INC. | $59.59 | 2024-2025 | Xpovio |
| Glaxosmithkline, LLC. | $57.97 | 2025 | Ojjaara, Blenrep |
| Daiichi Sankyo INC. | $55.91 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $50.14 | 2025 | |
| Array Biopharma INC | $49.68 | 2025 | Braftovi, Tukysa, Mektovi |
| Rigel Pharmaceuticals, INC. | $45.21 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Genentech USA, INC. | $43.04 | 2024-2025 | Venclexta, Polivy |
| Agios Pharmaceuticals, INC. | $42.14 | 2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $41.89 | 2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $32.48 | 2025 | |
| Acrotech Biopharma INC. | $30.11 | 2025 | Beleodaq |
| Iovance Biotherapeutics, INC. | $28.72 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $27.48 | 2025 | Orserdu |
| Servier Pharmaceuticals LLC | $26.49 | 2025 | |
| Verastem, INC. | $24.22 | 2025 | Avmapki Fakzynja Co-Pack |
| Pharmaessentia USA Corporation | $22.88 | 2024 | Besremi |
| Coherus Oncology, INC. | $22.84 | 2025 | Loqtorzi |
| Emd Serono, INC. | $22.79 | 2025 | |
| Lilly USA, LLC | $20.82 | 2024 | Verzenio |
| Alexion Pharmaceuticals, INC. | $19.14 | 2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $19.02 | 2025 | Danziten |
| Recordati_rare_diseases_inc. | $18.74 | 2025 | Enjaymo |
| Abbvie INC. | $18.07 | 2025 | |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Incyte Corporation | $15.63 | 2024 | Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $15.14 | 2025 | Akynzeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.